Real-World Study Finds CSL Seqirus' Cell-Based Flu Vaccine More Effective, Stock Climbs

(RTTNews) - Tuesday, CSL Limited's (CMXHF) CSL Seqirus announced real-world evidence from the 2023/24 U.S. season for populations six months to 64 years, showing that cell-based influenza vaccines offer greater protection in preventing test-confirmed influenza compared to standard egg-based vaccines.

Moreover, the data estimate 19.8 percent relative vaccine effectiveness of cell-based quadrivalent influenza vaccines versus standard egg-based quadrivalent vaccines.

The improved protection results were consistently observed across pediatric and adult age subgroups as well as for at-risk populations.

The company expects the data to help healthcare providers to further reduce the burden of influenza on their patients.

Currently, CSL's stock is moving up 9.39 percent to $147.67 on the OTC Markets.